Horizon Pharma plc (HZNP) is a solid gainer this session, as its shares are up nearly 5%. The surge came after the company said that Actimmune (interferon gamma-1b), its experimental Friedreich’s ataxia treatment, has received fast-track designation from the FDA, a move that could speed approval.
“We commend the FDA for granting Fast Track designation for Actimmune in Friedreich’s ataxia to potentially help treat patients suffering from this debilitating disorder, for which there are no FDA approved treatments available,” said in a statement Timothy P. Walbert, chairman, president and CEO, Horizon Pharma plc. “We look forward to continuing our ongoing clinical development program as we evaluate Actimmune in this patient population.”
HZNP shares recently gained $1.20 to $28.51. In the past 52 weeks, shares of Dublin, Ireland-based specialty biopharmaceutical company have traded between a low of $7.85 and a high of $28.73. Shares are up 103.12% year-over-year and 111.95% year-to-date.